Recent Quotes
View Full List
My Watchlist
Create Watchlist
Indicators
DJI
Nasdaq Composite
SPX
Gold
Crude Oil
Markets
Stocks
ETFs
Tools
Overview
News
Currencies
International
Treasuries
Novo Nordisk A/S ADR
(NY:
NVO
)
142.74
-1.75 (-1.21%)
Official Closing Price
Updated: 7:00 PM EDT, Jun 28, 2024
Add to My Watchlist
Quote
Overview
Detailed Quote
Charting
Historical Prices
News
All News
News Headlines
Press Releases
Research
Quarterly Reports
Insider Filings
Other Filings
All News about Novo Nordisk A/S ADR
< Previous
1
2
3
4
5
6
7
8
9
...
51
52
Next >
3 Relatively Safe Growth Stocks You Can Buy and Hold
April 20, 2024
Low risk and high-reward potential? These stocks could offer both.
Via
The Motley Fool
3 Biotech Stocks Set to Double by 2028
April 20, 2024
These are three of the top biotech stocks set to double by 2028. Add them to your portfolio to maximize your potential gains.
Via
InvestorPlace
Got $500? 3 Healthcare Stocks to Buy and Hold Forever
April 19, 2024
Make the most of a modest investment by putting it into Intuitive Surgical, Bristol Myers Squibb, and Novo Nordisk.
Via
The Motley Fool
German Authority Gives Go Ahead To Novo Nordisk's Small Bolt On Acquisition As Danish Firm Seeks To Build Heart Drugs Pipeline
April 18, 2024
Novo Nordisk's acquisition of Cardior Pharmaceuticals clears regulatory hurdles, advancing cardiovascular treatment development with CDR132L. Learn about the promising phase 2 trials and strategic...
Via
Benzinga
Patients Find Weight Loss Drug Zepbound A Game Changer, But Makers See Production Delay Until 2025
April 18, 2024
Facing a shortage, GLP-1 weight loss drugs by Eli Lilly & Novo Nordisk struggle to meet demand. Learn about supply issues and efforts to address them, impacting availability till 2025.
Via
Benzinga
If You Invested $1000 In This Stock 5 Years Ago, You Would Have $5,200 Today
April 15, 2024
Via
Benzinga
How The Weight-Loss Bonanza Prompted A ResMed Sell-Off — But Could Soon Drive Shares Higher
April 18, 2024
ResMed stock reversed higher Thursday after an analyst suggested weight-loss drugs could drive CPAP use.
Via
Investor's Business Daily
Why Eli Lilly Stock Beat the Market Today While ResMed and AdaptHealth Sank
April 17, 2024
The company published some very good news from the lab, although it wasn't so encouraging for smaller rivals.
Via
The Motley Fool
Powell And The Great Indecision
April 16, 2024
In today’s presser, Powell basically said what he typically says. Higher for longer but maybe not as risks remain to the economy while inflation is too sticky.
Via
Talk Markets
Topics
Economy
Exposures
Economy
Interest Rates
These 3 Biotech Stocks Are Up 269% in 2024. Is There More to Come?
April 16, 2024
These three biotech stocks are leading the sector higher on upbeat news but is this as good as it gets or do they have more gas in the tank?
Via
InvestorPlace
Buyback Bonanza: The Top 7 ETFs to Profit From Corporate Cash Splurges
April 16, 2024
Profit from corporate cash splurges with these top ETFs targeting buyback strategies. Unlock potential gains in a volatile market.
Via
InvestorPlace
Topics
ETFs
Healthcare Stocks Are Lagging With Big Earnings Weeks Ahead
April 16, 2024
Healthcare stocks disappointed again last week with the XLV down over 3% and up only 1.65 % YTD, in a continued downtrend since March 28.
Via
Talk Markets
3 Pharma Stocks That Are Money-Printing Machines in 2024
April 15, 2024
The economy, and pharma industry, are projected to grow massively. You should invest in these top three pharma stocks.
Via
InvestorPlace
Topics
Economy
Exposures
Economy
Novo Nordisk and Ginkgo Bioworks Are Teaming Up. Here's Why That's Bullish for Both Stocks.
April 15, 2024
The collaboration could help solve challenges for both businesses.
Via
The Motley Fool
Better Buy: Bristol Myers Squibb or the Vanguard S&P 500 ETF?
April 15, 2024
Bristol Myers Squibb stock sports an attractive valuation and dividend yield. Is it a more compelling buy than the Vanguard S&P 500 ETF?
Via
The Motley Fool
Topics
Stocks
Exposures
US Equities
Better Growth Play: Merck or The Vanguard Growth Index Fund?
April 15, 2024
Merck's shares are trading in bargain territory. Are they a better growth play than this popular Vanguard fund?
Via
The Motley Fool
Novo Nordisk Arms Wegovy to Be a Triple Threat
April 15, 2024
Novo Nordisk has had success with Ozempic and Wegovy for Type 2 diabetes and obesity, seeks to expand indications to include cardio diseases and neuro disorders
Via
MarketBeat
NYSE:NVO is showing good growth, while it is not too expensive.
April 15, 2024
For those who appreciate growth without the sticker shock, NOVO-NORDISK A/S-SPONS ADR (NYSE:NVO) is worth considering.
Via
Chartmill
Viking Therapeutics: Strong Results In Obesity
April 13, 2024
With a potential best in class drug for oral and injectable use, Viking Therapeutics has to be on many Big Pharma/Bio acquisition wish lists, as the company represents a very scarce asset in the $100...
Via
Talk Markets
Nvidia Leads 5 Stocks Near Buy Points As S&P 500 Tests Key Level
April 13, 2024
AI leader Nvidia bucked the S&P 500 downdraft last week.
Via
Investor's Business Daily
Topics
Artificial Intelligence
Stocks
Exposures
Artificial Intelligence
US Equities
Novo Nordisk's Dominance In Obesity & Diabetes Drug Market Backed by Strong Pipeline: Analyst Gives Outperform Rating
April 12, 2024
BMO's coverage of Novo Nordisk, spotlighting its groundbreaking advancements in weight loss and diabetes drugs. Analysts foresee Novo and Eli Lilly maintaining dominance in the obesity market, fueled...
Via
Benzinga
Eli Lilly Suffers Legal Loss For Its Popular Weight Loss/Diabetes Drug In Lawsuit Against Florida Compounding Pharmacy
April 12, 2024
U.S. District Judge Roy Altman's ruling prohibits Eli Lilly from using state law to halt RXCompoundStore.com's marketing of its tirzepatide version. The court asserts federal law enforcement authority,...
Via
Benzinga
Topics
Lawsuit
Exposures
Financial
Legal
Novo Nordisk/Eli Lilly's Weight Loss Drugs Does Not Cause Suicidal Behaviors - After FDA, European Medicines Agency Says
April 12, 2024
The European Medicines Agency's Pharmacovigilance Risk Assessment Committee found no conclusive evidence linking GLP-1 receptor agonists to suicidal or self-injurious thoughts. Following thorough...
Via
Benzinga
Exposures
Product Safety
Why Wall Street Got Even More Excited About The Glucose Monitor — And How Dexcom, Abbott Labs Stand To Benefit
April 12, 2024
Continuous glucose monitors have spiked in popularity since the advent of weight-loss drugs. Is chronic disease at its end?
Via
Investor's Business Daily
7 A-Rated Aggressive Biotech Stocks to Bet On in 2024
April 12, 2024
We’re using the Portfolio Grader to find the best biotech stocks to buy in today’s market. Each of these stocks get top grades.
Via
InvestorPlace
Shed the Fat, Gain the Profits: 3 Weight-Loss Stocks to Own Until 2027
April 12, 2024
For investors looking for a way to play weight-loss stocks in this current backdrop, here are three top options to consider right now.
Via
InvestorPlace
What's Going On With Ginkgo Bioworks Stock?
April 11, 2024
Ginkgo Bioworks announced the expansion of its strategic partnership with Novo Nordisk A/S on Wednesday under a framework agreement that initially is contemplated to run over five years.Ginkgo said the...
Via
Benzinga
All-Time High Flyers: 7 Stocks to Buy as the Market Peaks
April 11, 2024
These stocks to buy have enjoyed big rallies and the gains look likely to continue in coming months even if the market does peak.
Via
InvestorPlace
3 Obesity Drug Stocks Set to Skyrocket as Demand Goes Wild
April 10, 2024
Discover top obesity drug stocks set to soar as demand surges. Eli Lilly, Novo Nordisk, & Dexcom lead with revolutionary treatments
Via
InvestorPlace
2 Healthcare Stocks to Buy Hand Over Fist in April
April 10, 2024
Don't wait too long to invest in these exciting stocks.
Via
The Motley Fool
< Previous
1
2
3
4
5
6
7
8
9
...
51
52
Next >
Data & News supplied by
www.cloudquote.io
Stock quotes supplied by Barchart
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the following
Privacy Policy
and
Terms and Conditions
.